Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge by Hwi Seo et al.
VETERINARY RESEARCH
Seo et al. Veterinary Research 2014, 45:13
http://www.veterinaryresearch.org/content/45/1/13RESEARCH Open AccessEffect of porcine circovirus type 2 (PCV2)
vaccination on PCV2-viremic piglets after
experimental PCV2 challenge
Hwi Won Seo, Changhoon Park, Kiwon Han and Chanhee Chae*Abstract
The objective of this study was to evaluate the effect of porcine circovirus type 2 (PCV2) vaccines on PCV2-viremic
and -seropositive piglets born from naturally PCV2-infected sows against postnatal PCV2 challenge. The experimental
design was aimed at mimicking commercial swine rearing conditions to evaluate the response of the PCV2 vaccine on
PCV2-viremic and -seropositive piglets after experimental PCV2 challenge. PCV2a (or 2b)-viremic piglets received a PCV2
vaccine at 21 days of age followed by a PCV2b (or 2a) challenge at 49 days of age (28 days post vaccination). The PCV2
vaccines elicited a high level of humoral (as measured by immunoperoxidase monolayer assay and neutralizing antibody
titers) and cellular (as measured by the frequency of PCV2-specific interferon-γ-secreting cells) immune response in the
PCV2-viremic piglets after vaccination even in the presence of maternally derived antibodies (MDA). The initial infection of
PCV2 in the pigs was not affected by PCV2 vaccination, however the challenging PCV2 was reduced by PCV2 vaccination
on PCV2-viremic pigs. The results from this study demonstrate that the PCV2 vaccine used in this study is effective at
reducing PCV2 viremia and lymphoid PCV2 DNA, even for PCV2-viremic pigs with passively acquired MDA at the time of
vaccination.Introduction
Porcine circovirus type 2 (PCV2), a small, non-enveloped,
single stranded circular DNA virus belonging to the genus
Circovirus of the family Circoviridae [1], is the causative
agent of several diseases and syndromes, collectively re-
ferred to as porcine circovirus-associated disease (PCVAD)
[2]. Among these conditions, postweaning multisystemic
wasting syndrome (PMWS) is the most important [3].
PCVAD has now been recognized worldwide and is consid-
ered to be an economically important global disease. Today,
most farms use a PCV2 vaccine for the control of PCVAD
since the first introduction of the PCV2 vaccine in 2006 [4].
Epidemiologic surveys have reported that 33-40% of
newborn and pre-suckle piglets are PCV2-viremic [5,6].
The PCV2-viremic piglets from PCV2-infected sows
were able to develop PMWS during the postnatal period
if they were postnatally infected with porcine parvovirus
[7]. In addition, piglets from PCV2-viremic sows were at
high risk for developing PCVAD at any time throughout* Correspondence: swine@snu.ac.kr
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reproduction in any medium, provided the ortheir life [8]. These results suggest that PCV2-viremic
piglets may be immune-compromised, resulting in im-
paired PCV2 immunizations at postnatal periods. Conse-
quently, immune-compromised PCV2-viremic piglets
may be one of the contributing factors for increasing
reports of apparent vaccine failure in late finisher pigs.
The vaccination of sows has been shown to reduce the
prevalence of PCV2 viremia in their piglets under field
conditions [9]. Additionally, vaccination of the sow was
able to protect piglets against a PCV2 challenge up to 8
weeks of age [10]. This may explain why piglet vaccination
is likely to become more popular among pig producers
worldwide [4]. The results from one experimental study
indicated that PCV2 vaccines can be efficacious in PCV2-
viremic pigs against triple challenged with PCV2, porcine
reproductive and respiratory syndrome virus (PRRSV) and
porcine parvovirus (PPV) [11]. However, this study is fo-
cused on the evaluation of the efficacy of the PCV2 vaccine
against triple challenge rather than the effect of PCV2 vac-
cination on PCV2-viremic pigs. Hence, this study aimed to
evaluate the effect of PCV2 vaccines on PCV2-viremic pigs
from naturally PCV2-infected sows against postnatal PCV2. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PCV2a (or 2b)-viremic pigs were challenged with PCV2b




A total of 105 colostrum-fed, cross-bred, conventional
piglets were purchased at 7 days of age, derived from 20
sows on a commercial farm. Gilts and sows were not
vaccinated for PCV2 on this farm. Clinical signs indica-
tive of PCVAD had not been observed on the farm. Upon
arrival, all pigs were tested and found to be negative for
PRRSV and Mycoplasma hyopneumoniae according to rou-
tine serological testing.
Among the 105 pigs, 84 pigs were PCV2 seropositive
and either PCV2a- or PCV2b-viremic. All PCV2-viremic
pigs were the same PCV2 type as their dam. PCV2-
viremic and -seropositive piglets had positive immuno-
peroxidase monolayer assay (IPMA) titers (ranging from
8 to 12 log2) for the detection of total PCV2 antibodies,
neutralizing antibody (NA) titers (ranging from 7.0 to
9.0 log2), and genomic copies of PCV2 DNA load in the
blood (ranging from 3.5 to 4.5 log10 PCV2 DNA copies/
mL). The PCV2-viremic and -seropositive pigs used in
this study had similar PCV2 viremia and serological
profiles to naturally infected piglets (mean log10 PCV2
DNA copies ranging from 3.75 to 4.58 [5] and mean log2
IPMA titers ranging from 10 to 12 [12]). Twenty-one pigsTable 1 Study design with exposed, vaccination, and challe
challenge (dpc)a
Group Viremia (−42 dpc) Va
PCV2a PCV2b Vaccine A
1 + - +
2 + - -
3 + - +
4 + - -
5 + - -
6 + - -
7 - + +
8 - + -
9 - + +
10 - + -
11 - + -
12 - + -
13 - - -
14 - - -
15 - - -
aThere were seven animals in each group, and necropsy was performed at 21 dpc (
bVaccine A: inactivated chimeric PCV1-2 vaccine (Fostera PCV, Zoetis, Madison, NJ, U
cVaccine B: experimental inactivated PCV2 vaccine.were non-PCV2-viremic and seronegative for PCV2. The
pigs were blocked into PCV2a, PCV2b and negative groups
prior to randomization and housed separately within the
facility in an environmentally controlled building as previ-
ously described [13].
PCV2 vaccines
Commercial and experimental PCV2 vaccines were used
in this study. The commercial PCV2 vaccine is an inacti-
vated chimeric PCV1-2 vaccine (Fostera PCV, Zoetis,
Madison, NJ, USA). The experimental inactivated PCV2
vaccine contained inactivated PCV2b (at a titer of 106
fluorescent antibody infectious dose50/mL) and an
aluminum hydroxide gel adjuvant (10% of volume in
1 mL/dose). PCV2 vaccines were used and adminis-
tered according to the manufacturer’s instructions with
regards to time and route of injection (intramuscularly
in the right side of the neck).
Experimental design
The experimental design is summarized in Table 1. A
total of 105 pigs were randomly divided into 15 groups
(7 pigs per group). Two groups of PCV2a-viremic pigs
(groups 1 and 3) and PCV2b-viremic pigs (groups 7 and
9) were immunized with an inactivated chimeric PCV1-
2 vaccine administered as a 2.0 mL dose at 21 days
of age based on the manufacturer’s recommendations.
Another 2 groups of PCV2a-viremic pigs (groups 2 and
4) and PCV2b-viremic pigs (groups 8 and 10) werenge statuses for PCV2 at different days post
ccination (−28 dpc) Challenge (0 dpc)
















70 days of age) in all cases.
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cine administered intramuscularly as a 1.0 mL dose at
21 days of age.
At 49 days of age (0 days post challenge (dpc)), the
PCV2a-viremic pigs (groups 1, 2 and 5) and PCV2b-
viremic pigs (groups 7, 8, and 11) were challenged
intranasally with 2 mL of PCV2b (strain SNUVR000463
(GenBank no. KF871068); 5th passage; 1.0 × 105 tissue
culture infective dose of 50% (TCID50)/mL) or PCV2a
(strain SNUVR000032 (GenBank no. KF871067); 5th pas-
sage; 1.0 × 105 TCID50/mL), respectively. The non-PCV2-
viremic pigs in groups 13 and 14 remained unvaccinated
and were challenged with PCV2a or PCV2b at 49 days of
age. The non-PCV2-viremic pigs in group 15 remained
unvaccinated and unchallenged, and they served as the
negative control group.
Blood was collected at −42, −28, 0, 7, 14, and 21 dpc.
For euthanasia, pigs were sedated by an intravenous in-
jection of sodium pentobarbital and then euthanized by
electrocution [14]. Superficial inguinal lymph nodes were
collected for histopathology and in situ hybridization (ISH).
Methods used in this study were approved by the Seoul
National University Institutional Animal Care and Use
Committee.Quantification of PCV DNA in blood
DNA was extracted from serum samples using the
QIAamp DNA mini kit. DNA extracts were used to
quantify PCV2a and PCV2b genomic DNA copy num-








IPMA and NA tests were performed using both a challen-


























bEnzyme-linked immunospot (ELISPOT) assay
The PCV2a and PCV2b antigens were prepared as previ-
ously described [8] and used as stimuli. The numbers of
PCV2-specific interferon-γ-secreting cells (IFN-γ-SC)
were determined in peripheral blood mononuclear cells
(PBMC) as previously described [18,19].0





Figure 1 Quantification of PCV2b DNA in sera. Mean values of
the genomic copy number of PCV2b DNA in serum from four
different groups (commercial inactivated chimeric PCV1-2 vaccinated
PCV2b-challenged PCV2a-viremic pigs (group 1), experimental inacti-
vated PCV2 vaccinated PCV2b-challenged PCV2a-viremic pigs (group
2), unvaccinated PCV2b-challenged PCV2a-viremic pigs (group 5),
and unvaccinated PCV2b-challenged non-PCV2-viremic pigs (group
14)) at different days post challenge. Different letters (a, b, and c)
indicate statistically significant differences (P < 0.05) among groups.Histopathology and in situ hybridization
For the morphometric analysis of histopathological
changes in lymph nodes, three superficial inguinal lymph
node sections were examined “blindly” as previously de-
scribed [20]. Genotype-specific in situ hybridization
(ISH) was used to detect PCV2a and PCV2b, respect-
ively, in formalin-fixed, paraffin-embedded tissues [21].
Morphometric analysis of ISH was carried out as previ-
ously described [13].Statistical analysis
Summary statistics were calculated for all groups to as-
sess the overall quality of the data, including normality.
The values of genomic copies of serological data and
PCV2 viremia were transformed log2 and log10, respect-
ively, prior to analysis. Continuous data (genomic copies
of PCV2 DNA, serology and PCV2-specific IFN-γ-SC,
number of in situ hybridization positive cells) were ana-
lyzed with a repeated measures analysis of variance
(ANOVA). If the repeated measures ANOVA showed a
significant effect, a one-way ANOVA with pairwise test-
ing using the Tukey’s adjustment was performed at
each time point. If the distribution of variables was not
normal, the non-parametric Kruskal-Wallis and Mann-
Whitney tests were used to analyze the data. Discrete data
(lymphoid lesion score) were analyzed by Chi-square and/
or the Fisher’s exact test. A linear regression was performed
to determine the correlation between PCV2 antibody titer
at the day of vaccination (21 days of age) and the increment
of PCV2 antibody titer at 28 days post vaccination (delta
value, defined as PCV2 antibody titer at 28 days post
vaccination minus PCV2 antibody titer at the day of
vaccination).
Results
PCV2 DNA in sera from PCV2a-viremic pigs
The results of PCV2b DNA in the blood from PCV2a-
viremic pigs are summarized in Figure 1. PCV2a DNA was
detected in the blood of PCV2a-viremic pigs throughout
the experimental study. The PCV2a-viremic pigs that were
vaccinated and then challenged with PCV2b (groups 1 and
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copies of PCV2b DNA in the blood compared to the un-
vaccinated PCV2b-challenged PCV2a-viremic pigs (group
5) and the unvaccinated PCV2b-challenged non-PCV2-
viremic pigs (group 14) at 7 and 21 dpc (Figure 1). There
was no significant difference in the log10 transformed gen-
omic copy numbers (ranging from 3.27 to 4.12 log10 PCV2a
DNA copies/mL) of PCV2a DNA in PCV2a-viremic pigs
regardless of PCV2 vaccination and challenge among the 6
groups (groups 1, 2, 3, 4, 5, and 6). No PCV2b was detected
in the blood of unvaccinated unchallenged PCV2a-viremic
(group 6) and non-PCV2-viremic negative control pigs
(group 15).
PCV2 DNA in sera from PCV2b-viremic pigs
The results of PCV2a DNA in the blood from PCV2b-
viremic pigs are summarized in Figure 2. PCV2b DNA was
detected in the blood of PCV2b-viremic pigs throughout
the experimental study. The PCV2b-viremic pigs that were
vaccinated and then challenged with PCV2a (groups 7 and
8) had a significantly (P < 0.05) lower number of genomic
copies of PCV2a DNA in the blood than the unvaccinated
PCV2a-challenged PCV2b-viremic pigs (group 11) and the
unvaccinated PCV2a-challenged non-PCV2-viremic pigs
(group 13) at 7, 14, and 21 dpc (Figure 2). There was no
significant difference in the log10 transformed genomic
copy numbers (ranging from 3.11 to 4.32 log10 PCV2b
DNA copies/mL) of PCV2b DNA in PCV2b-viremic pigs
regardless of PCV2 vaccination and challenge among 6
groups (groups 7, 8, 9, 10, 11, and 12). PCV2a DNA was










































Figure 2 Quantification of PCV2a DNA in sera. Mean values of
the genomic copy number of PCV2a DNA in serum from four
different groups (commercial inactivated chimeric PCV1-2 vaccinated
PCV2a-challenged PCV2b-viremic pigs (group 7), experimental inacti-
vated PCV2 vaccinated PCV2a-challenged PCV2b-viremic pigs (group
8), unvaccinated PCV2a-challenged PCV2b-viremic pigs (group 11),
and unvaccinated PCV2a-challenged non-PCV2-viremic pigs (group
13)) at different days post challenge. Different letters (a, b, and c)
indicate statistically significant differences (P < 0.05) among groups.challenged groups (7, 8, 11, and 13) regardless of PCV2
vaccination. No PCV2a was detected in the blood of unvac-
cinated unchallenged PCV2b-viremic (group 12) and non-
PCV2-viremic negative control pigs (group 15).
Immunoperoxidase monolayer assay titers from PCV2a
(or 2b)-viremic pigs
The results of IPMA titers from PCV2a- and PCV2b
viremic pigs are summarized in Figures 3A and 4A, re-
spectively. The vaccinated PCV2b-challenged PCV2a-
viremic pigs (groups 1 and 2) had significantly (P < 0.05)
higher PCV2-specific IPMA titers than the unvaccinated
PCV2b-challenged PCV2a-viremic pigs (group 5) at 0, 7,
and 14 dpc, and the unvaccinated unchallenged PCV2a-
viremic pigs (group 6) at 0, 7, 14, and 21 dpc (Figure 3A).
The vaccinated PCV2a-challenged PCV2b-viremic pigs
(groups 7 and 8) had significantly (P < 0.05) higher IPMA
titers than the unvaccinated PCV2a-challenged PCV2b-
viremic pigs (group 11) at 0, 7, and 14 dpc, and the unvac-
cinated unchallenged PCV2b-viremic pigs (group 12) at 0,
7, 14, and 21 dpc (Figure 4A). No PCV2-specific IPMA
titers were detected in unvaccinated unchallenged non-
PCV2-viremic pigs (group 15).
Neutralizing antibody titers from PCV2a (or 2b)-viremic pigs
The results of NA titers from PCV2a- and PCV2b-viremic
pigs are summarized in Figures 3B and 4B, respectively.
The vaccinated PCV2b-challenged PCV2a-viremic pigs
(groups 1 and 2) had significantly (P < 0.05) higher PCV2-
specific NA titers than the unvaccinated PCV2b-challenged
PCV2a-viremic pigs (group 5) at 0, 7, and 14 dpc
(Figure 3B). The vaccinated PCV2a-challenged PCV2b-
viremic pigs (groups 7 and 8) had significantly (P < 0.05)
higher NA titers than the unvaccinated PCV2a-challenged
PCV2b-viremic pigs (group 11) at 0, 7, 14, and 21 dpc
(Figure 4B). No PCV2-specific NA titers were detected
in unvaccinated unchallenged non-PCV2-viremic pigs
(group 15).
PCV2-specific interferon- γ-secreting cells from PCV2a
(or 2b)-viremic pigs
The results of PCV2-specific IFN-γ-SC from PCV2a-
and PCV2b-viremic pigs are summarized in Figures 3C
and 4C, respectively. The vaccinated PCV2b-challenged
PCV2a-viremic pigs (groups 1 and 2) had significantly
(P < 0.05) higher mean numbers of PCV2-specific IFN-γ-
SC than the unvaccinated PCV2b-challenged PCV2a-
viremic pigs (group 5) at 0, 7, and 14 dpc (Figure 3C).
The vaccinated PCV2a-challenged PCV2b-viremic pigs
(groups 7 and 8) had significantly (P < 0.05) higher mean
numbers of PCV2a- and PCV2b-specific IFN-γ-SC than
the unvaccinated PCV2a-challenged PCV2b-viremic pigs
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Figure 3 PCV2b-specific humoral and cell-mediated immune
responses. Log2 transformed group means for PCV2b-specific
immunoperoxidase monolayer assay (IPMA) titers (A), neutralizing
antibody (NA) titers (B), and frequency of PCV2b-specific interferon-
γ-secreting cells (IFN-γ-SC)/106 peripheral blood mononuclear cells
(PBMC) (C) from 7 different groups (commercial inactivated chimeric
PCV1-2 vaccinated PCV2b-challenged PCV2a-viremic pigs (group 1),
experimental inactivated PCV2 vaccinated PCV2b-challenged PCV2a-
viremic pigs (group 2), commercial inactivated chimeric PCV1-2
vaccinated unchallenged PCV2a-viremic pigs (group 3), experimental
inactivated PCV2 vaccinated unchallenged PCV2a-viremic pigs
(group 4), unvaccinated PCV2b-challenged PCV2a-viremic pigs
(group 5), unvaccinated unchallenged PCV2a-viremic pigs (group 6),
and unvaccinated PCV2b-challenged non-PCV2-viremic pigs (group 14)).
Different letters (a, b, c, and d) indicate statistically significant differences
(P< 0.05) among groups.
Seo et al. Veterinary Research 2014, 45:13 Page 5 of 9
http://www.veterinaryresearch.org/content/45/1/13specific IFN-γ-SC was observed in unvaccinated unchal-
lenged non-PCV2-viremic pigs (group 15).
Effects of maternally derived antibodies on PCV2 vaccine
seroconversion
The results show a significant negative correlation
of humoral immune response with vaccination with
a commercial inactivated chimeric PCV1-2 vaccine
(Fostera PCV, Zoetis) in PCV2a- and PCV2b-viremic
pigs (r = −0.8299, P = 0.017 for IPMA titers and
r = −0.8467, P = 0.012 for NA titers) and vaccination with
an experimental inactivated PCV2 vaccine in PCV2a- and
PCV2b-viremic pigs (r = −0.7984, P = 0.023 for IPMA titers
and r = −0.8208, P = 0.012 for NA titers).
Lymphoid lesion and in situ hybridization score from
PCV2a (or 2b)-viremic pigs
The results of lymphoid lesion and ISH score from
PCV2a- and PCV2b-viremic pigs are summarized in
Table 2. The pigs in six groups (group 1, 2, 3, 4, 5, and
6) had significantly (P < 0.05) lower lymphoid lesion
scores and ISH PCV2b scores than the unvaccinated
PCV2b-challenged non-PCV2-viremic pigs (group 14).
The vaccinated PCV2a-challenged PCV2b-viremic pigs
(groups 7 and 8) had significantly (P < 0.05) lower ISH
PCV2a scores than the unvaccinated PCV2a-challenged
PCV2b-viremic pigs (group 11). No hybridization signals
for PCV2a and PCV2b were detected in lymph nodes
from unvaccinated unchallenged non-PCV2-viremic pigs
(group 15).
Discussion
The use of vaccination to immunize and protect pigs
against PCV2 infection has been widely evaluated under
experimental and field conditions [10,18,22-26]. Numer-
ous experiments have shown that PCV2 vaccines are
highly efficacious at protecting pigs against PCV2 infec-
tion. Ideally, PCV2 vaccination should be administered
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Figure 4 PCV2a-specific humoral and cell-mediated immune
responses. Log2 transformed group means for PCV2a-specific
immunoperoxidase monolayer assay (IPMA) titers (A), neutralizing
antibody (NA) titers (B), and frequency of PCV2a-specific interferon-
γ-secreting cells (IFN- γ-SC)/106 peripheral blood mononuclear cells
(PBMC) (C) from 7 different groups (commercial inactivated chimeric
PCV1-2 vaccinated PCV2a-challenged PCV2b-viremic pigs (group 7),
experimental inactivated PCV2 vaccinated PCV2a-challenged PCV2b-
viremic pigs (group 8), commercial inactivated chimeric PCV1-2
vaccinated unchallenged PCV2b-viremic pigs (group 9), experimental
inactivated PCV2 vaccinated unchallenged PCV2b-viremic pigs
(group 10), unvaccinated PCV2a-challenged PCV2b-viremic pigs
(group 11), unvaccinated unchallenged PCV2b-viremic pigs (group
12), and unvaccinated PCV2a-challenged non-PCV2-viremic pigs
(group 13)). Different letters (a, b, c, and d) indicate statistically
significant differences (P < 0.05) among groups.
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the field, vaccination is likely administered routinely in
the face of maternal immunity and infection in the field.
Field data indicate that PCV2 vaccines are not inhibited
by MDA when efficacy is assessed in terms of the
reduction of PCV2-associated lesions and viral load in the
serum [23,25]. Hence, MDA interference does not signifi-
cantly hamper vaccine efficacy [18,23,25]. However, little
scientific information is available describing the effect of
PCV2 vaccination on PCV2-viremic and -seropositive pigs.
The PCV2-viremic and -seropositive pigs used in this study
had similar PCV2 viremia and serological profiles to
naturally infected piglets [5,12]. Therefore, the experi-
mental design attempted to mimic commercial swine
rearing conditions to evaluate the response of PCV2-
viremic and -seropositive piglets after PCV2 vaccin-
ation and experimental PCV2 challenge.
In the present study, the vaccinated PCV2a-viremic
pigs were challenged with PCV2b to differentiate initial
PCV2 infection from challenging virus. PCV2 vaccines
significantly reduced the amount of challenging PCV2a
(or 2b) in the blood of PCV2b (or 2a)-viremic pigs that
received a PCV2 vaccine and were subsequently chal-
lenged. The reduction of PCV2 viremia by the vaccine
plays a critical role in controlling PCV2 infection [4]. A
high PCV2 viremia has already been shown to be associ-
ated with the development of PCVAD [27-29]. There-
fore, increased PCV2 viremia equates to an increased
risk of developing PCVAD. The results of the present
study demonstrate that PCV2 vaccination can protect
PCV2-viremic pigs from a subsequent PCV2 challenge.
Despite the significant reduction of the challenging
PCV2 in the blood as a result of PCV2 vaccination,
PCV2a (or 2b)-viremic pigs that received a PCV2 vac-
cine followed by a PCV2b (or 2a) challenge retained a
PCV2a (or 2b)-viremia as a result of previous exposure
until the termination of the experimental study at 21
dpc. The failure to reduce or eliminate previously
Table 2 Results of lymphoid lesion score and the number
of in situ hybridization (ISH) positive cells for PCV2a and






In situ hybridization score
PCV2a PCV2b
2a 7 0.47 ± 0.35a,b 0.71 ± 1.25b 10.42 ± 5.22b
8 0.51 ± 0.42a,b 0.85 ± 1.46b 11.14 ± 5.89b
11 0.71 ± 0.69a,b 8.14 ± 6.06a 10.7 ± 5.93b
13 1.57 ± 0.53c 30.71 ± 10.96c 0.0 ± 0.0a
2b 1 0.53 ± 0.52a,b 9.14 ± 6.56a 2.0 ± 2.51a
2 0.43 ± 0.53a,b 7.28 ± 6.87a 2.42 ± 3.1a
5 0.86 ± 0.48b 8.42 ± 5.15a 7.14 ± 4.14b
14 2.00 ± 0.81c 0.0 ± 0.0b 37.29 ± 8.96c
Non-challenged 3 0.29 ± 0.49a 5.71 ± 6.23a 0.0 ± 0.0a
4 0.23 ± 0.41a 6.14 ± 5.49a 0.0 ± 0.0a
6 0.31 ± 0.37a 8.57 ± 6.07a 0.0 ± 0.0a
9 0.35 ± 0.39a,b 0.0 ± 0.0b 8.85 ± 5.17b
10 0.41 ± 0.38a,b 0.0 ± 0.0b 7.14 ± 4.77b
12 0.43 ± 0.49a,b 0.0 ± 0.0b 9.14 ± 5.27b
15 0.0 ± 0.0a 0.0 ± 0.0b 0.0 ± 0.0a
Different letters (a, b, and c) indicate significant (P < 0.05) difference
among groups.
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longed PCV2 viremia. It has been reported that PCV2
can maintain viremia up to 140 dpc for PCV2a and 69
dpc for PCV2b [30,31]. The prolonged previously en-
countered PCV2 viremia may be transmitted to suscep-
tible animals following direct contact with pigs and can
perpetuate the infection within a herd. Further study is
needed to determine the effect of previous exposure to
PCV2 after PCV2 vaccination.
The efficacy of PCV2 vaccination in PCV2-viremic
piglets can be affected by the presence of MDA. There-
fore, the PCV2-viremic piglets may face potential
interference from PCV2 antibodies present at the time
of vaccination. Whether the efficacy of vaccination in
piglets can be affected by the presence of MDA is con-
troversial. Piglets with high IPMA titers (> 10 log2)
have been shown to experience interference with the
development of a humoral immune response following
vaccination, while piglets with moderate titers (< 8
log2) do not [22]. In the present study, PCV2-viremic
piglets had moderate IPMA (< 8 log2) and NA (< 7
log2) titers at the time of vaccination. Moreover, the
PCV2 vaccine elicited a high level of IPMA and NA ti-
ters, and the frequency of IFN-γ-SC in PCV2-viremic
and -seropositive piglets was high even in the presence
of MDA. These two immunological parameters are re-
sponsible for the reduction of PCV2 viremia andcontrol PCV2 infection [28,32]. These data suggest
that preexisting, moderate levels of MDA do not
interfere with the development of an active immune
response after PCV2 vaccination in PCV2-viremic
piglets.
There were no significant differences in the frequency
of PCV2-specific IFN-γ-SC in response to the whole
virus when either PCV2a or PCV2b was used as a recall
antigen, as demonstrated in a previous study [33]. The
PCV2a-based commercial vaccine and the PCV2b-based
experimental vaccine induced similar profiles of PCV2a-
and PCV2b-specific IFN-γ-SC in the PCV2a- and PCV2b-
viremic pigs when either PCV2a or PCV2b was used as
a recall antigen. These results suggest the existence of
conserved immunodominant T-cell epitopes between
both genotypes, which is further supported by the
cross-protection of PCV2a-based vaccines against a
PCV2b challenge [34,35]. These results are clinically
significant because all the commercial PCV2 vaccines
currently used worldwide are based on the PCV2a
genotype.
Rather than PCV2 vaccination, the reduction of PCV2b
(or 2a) viremia in pigs previously exposed to PCV2a (or 2b)
may be due to cross protection between the two genotypes.
PCV2a- (or 2b-) viremic pigs that were challenged with
PCV2b (or 2a) had significantly reduced levels of challen-
ging PCV2 in the blood. These results were in agreement
with a previous study [36]. Although cross protec-
tion between PCV2 and PCV2b exists [36], PCV2a-
viremic pigs that received a PCV2 vaccine followed
by a PCV2b challenge had a significantly lower num-
ber of genomic copies of challenging PCV2b in the
serum than the unvaccinated PCV2a-viremic pigs
that were only challenged with PCV2b. These results
indicate that active immune responses by PCV2 vac-
cination, rather than natural infection or passively
transferred MDA, play an important role in reducing
PCV2b viremia in PCV2a-viremic pigs that received
a PCV2 vaccine followed by a PCV2b challenge and
vice versa.
PCV2-associated microscopic lesions were not prom-
inent in this study because the pigs were challenged
with PCV2 alone rather than co-challenged with other
viruses, such as PRRSV or PPV. Vaccination effectively
reduced the number of PCV2-associated microscopic
lesions and the level of PCV2 DNA in the lymphoid tissues
of PCV2-viremic piglets that received a PCV2 vaccine
followed by a PCV2 challenge. Many pig producers may
believe that PCV2-viremic or -seropositive piglets con-
tribute to vaccine failure. The results from this study
demonstrate that the PCV2 vaccine was effective in re-
ducing PCV2 viremia and lymphoid PCV2 DNA even
when used on PCV2-viremic pigs with passively ac-
quired MDA at the time of vaccination.
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